Jason Tardio joined Ovid Therapeutics as Chief Commercial Officer in November 2019. Before joining Ovid, Mr. Tardio served as Vice President, Head of the Multiple Sclerosis franchise at Novartis. There, he was responsible for developing and managing all aspects of the U.S. commercial plan, brand P&L, strategy development, and go-to-market modeling. Prior to Novartis, Mr. Tardio held roles of increasing responsibility at Biogen where most recently he served as GM, Managing Director for Biogen’s Latin America South affiliate. Earlier at Biogen, Jason held a wide range of sales and marketing roles of increasing responsibility, including positions in global commercial strategy, the U.S. business unit and at the international affiliate level. His 20 years of commercial experience in the biopharmaceutical industry began at Wyeth and Sepracor, with roles in sales, sales training and marketing. Jason holds a Bachelor of Science from The College of New Jersey and an MBA in pharmaceutical marketing from St. Joseph’s University.
Rare Disease Therapies are No Longer Rare: Can the US Healthcare Reimbursement System Handle Chronic Treatments for Orphan Diseases
Cures to devastating diseases, such as Hepatitis C drugs and gene therapies, are being developed…